Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
Provided herein are nucleic acid sequences encoding hepatitis B virus (HBV) core proteins, surface antigen proteins, fragments and combinations thereof as well as genetic constructs/vectors and vaccines that express said protein sequences. These vaccines are able to induce an immune response peripherally and in the liver by recruiting both cellular and humoral agents. Also provided are methods for prophylactically and/or therapeutically immunizing individuals against HBV. The combination vaccine can also be used for particular design vaccines for particular levels of immune responses to HBV challenge.
1. An immunogenic composition comprising:
(a) a nucleic acid molecule encoding one or more proteins selected from the group consisting of: SEQ ID NO:10 and a protein that is 95% identical to the full length amino acid sequence of SEQ ID NO:10; or
(b) a nucleic acid molecule encoding one or more proteins selected from the group consisting of: SEQ ID NO: 12 and a protein that is 95% identical to the full length amino acid sequence of SEQ ID NO:12.
2. The immunogenic composition of claim 1 , further comprising:
(c) a nucleic acid molecule encoding SEQ ID NO:2.
3. The immunogenic composition of claim 1 , comprising:
(a) a nucleic acid molecule encoding one or more proteins selected from the group consisting of: SEQ ID NO:10 and a protein that is 95% identical to the full length amino acid sequence of SEQ ID NO:10;
(b) a nucleic acid molecule encoding one or more proteins selected from the group consisting of: SEQ ID NO: 12 and a protein that is 95% identical to the full length amino acid sequence of SEQ ID NO:12; and
(c) a nucleic acid molecule encoding SEQ ID NO:2.
4. The immunogenic composition of claim 3 , wherein the nucleic acid molecules comprise one or more nucleotide sequences selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:9, and SEQ ID NO:11.
5. The immunogenic composition of claim 1 , wherein the nucleic acid molecules are plasmids.
6. The immunogenic composition of claim 1 , wherein the nucleic acid molecules are incorporated into viral particles.
7. The immunogenic composition of claim 1 further comprising an adjuvant molecule.
8. The immunogenic composition of claim 7 , wherein the adjuvant is IL-12, IL-15, IL-28, or RANTES.
9. A method of inducing an immune response against an HBV antigen comprising administering the immunogenic composition of claim 1 to a subject.